Search

Tilmann M Brotz

from Berkeley, CA
Age ~60
Get Report
Also known as:
Tilmann Svenja Brotz, Tilmann Bortz, Brotz Tilmann, Bortz Tilmann
Phone and address:
830 Camelia St, Berkeley, CA 94710
(510) 524-5713
Related to:
Leander BrotzLeo K Brotz, 33Linnea P Brotz, 31Svenja Brotz, 59Conrad L Brotz, 35
Connected to:
Jamie B Brotz, 41Ralph R Brotz, 80Leo D Brotzel, 72Brian Brotzki, 49Michele L Brotzki, 45Brian N Brotzman, 63Carl M Brotzman, 45Cynthia A Brotzman, 60James E Brotzman, 91John P Brotzman, 56

Tilmann Brotz Phones & Addresses

  • 830 Camelia St, Berkeley, CA 94710 (510) 524-5713
  • 548 Santa Clara Ave, Berkeley, CA 94707 (510) 524-5713
  • 46 Kensington Rd, Kensington, CA 94707 (510) 524-5713
  • Highland, MD
  • Highland Bch, MD
  • Alameda, CA
  • 830 Camelia St, Berkeley, CA 94710

Resumes

Resumes

Tilmann Brotz Photo 1

Principal

View page
Location:
Berkeley, CA
Industry:
Pharmaceuticals
Work:
konzept drug development consulting - San Francisco Bay Area since Sep 2011
Principal
VIA Pharmaceuticals, Inc. - San Francisco Bay Area Jul 2008 - Sep 2011
Vice President, Preclinical Research & Development
VIA Pharmaceuticals - San Francisco Bay Area May 2007 - Jul 2008
Sr. Director, Preclinical Development
Renovis, Inc. - San Francisco Bay Area Mar 2001 - May 2007
Director, Preclinical Development
National Cancer Institute (NIH) - Washington D.C. Metro Area Jun 1999 - Feb 2001
Staff Scientist and Head of the Microscopy and Digital Imaging Facility
Education:
University of California, Berkeley 1996 - 1999
Eberhard-Karls-Universität Tübingen 1992 - 1995
Eberhard-Karls-Universität Tübingen / University of Tuebingen 1992
Universidade de São Paulo 1988 - 1988
Skills:
Drug Development
Clinical Development
Biotechnology
Pharmacology
Drug Discovery
Clinical Trials
Cro
Pharmaceutical Industry
Life Sciences
Toxicology
Ind
Clinical Research
Biomarkers
Microscopy
Confocal Microscopy
Project Management
Translational Research
Lifesciences
Preclinical Development
Biomarker Discovery
Due Diligence
Drug Metabolism
Cardiovascular Medicine
Outsourcing Management
Medical Imaging
Neuroscience
Metabolic Diseases
Electrophysiology
Drug Design
Drug Development Strategy
Clinical Pharmacology
Neurodegenerative Diseases
Research Project Management
Data Analysis
Virtual Teams
Digital Imaging
Pharmaceuticals
Website Development
Accounting
Ms Project
Pharmaceutical Development
Spotfire
Drug Development Consulting
Clinicaltrials.gov Administration
Regulatory Affairs
Languages:
English
German
Portuguese
Tilmann Brotz Photo 2

Tilmann Brotz

View page

Business Records

Name / Title
Company / Classification
Phones & Addresses
Tilmann M. Brotz
Chestnut & Vine Floral Design
Business Services · Floral and Event Design
830 Camelia St, Berkeley, CA 94710

Publications

Us Patents

Phenylalkyl N-Hydroxyureas For Treating Leukotriene Related Pathologies

View page
US Patent:
20130190514, Jul 25, 2013
Filed:
Jul 25, 2011
Appl. No.:
13/813082
Inventors:
Rebecca Taub - Villanova PA, US
Tilmann Brotz - Berkeley CA, US
John Franc - Newtown PA, US
Larry Cohen - New York NY, US
Hemantkumar H. Patel - Bodakdev, IN
Sanjay R. Chemburkar - Gurnee IL, US
David P. Sawick - Gurnee IL, US
Assignee:
TALLIKUT PHARMACEUTICALS, INC. - San Francisco CA
International Classification:
C07D 333/20
US Classification:
549 77
Abstract:
The method of treating patients by administering N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propynyl]-N-hydroxyurea for treatment of leukotriene related pathologies, and compositions for this use.

Phenylalkyl N-Hydroxyureas For Treating Leukotriene Related Pathologies

View page
US Patent:
20130317078, Nov 28, 2013
Filed:
Jun 20, 2013
Appl. No.:
13/923071
Inventors:
Tilmann Brotz - Berkeley CA, US
John Franc - Newtown PA, US
Lawrence K. Cohen - Oakland CA, US
Hemantkumar H. Patel - Ahmedabad, IN
Sanjay R. Chemburkar - Gurnee IL, US
David P. Sawick - Gurnee IL, US
International Classification:
A61K 31/381
US Classification:
514438, 549 77
Abstract:
The method of treating patients by administering N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propynyl]-N-hydroxyurea for treatment of leukotriene related pathologies, and compositions for this use.

Phenylalkyl N-Hydroxyureas For Treating Leukotriene Related Pathologies

View page
US Patent:
20120029048, Feb 2, 2012
Filed:
Feb 10, 2011
Appl. No.:
13/025106
Inventors:
Rebecca Taub - Villanova PA, US
Tilmann Brotz - Berkeley CA, US
John Franc - Newtown PA, US
Larry Cohen - Oakland CA, US
Hemantkumar H. Patel - Bodakdev Ahmedabad, IN
Sanjay R. Chemburkar - Gurnee IL, US
David P. Sawick - Gurnee IL, US
Assignee:
VIA Pharmaceuticals, Inc. - Fort Washington PA
International Classification:
A61K 31/381
A61P 9/10
A61P 25/28
A61P 19/02
A61P 11/06
A61P 1/00
C07D 333/20
A61P 11/00
US Classification:
514438, 549 75
Abstract:
The method of treating patients by administering N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propynyl]-N-hydroxyurea for treatment of leukotriene related pathologies and compositions for this use.

Ocular Formulations Comprising Geranylgeranylacetone Derivatives For Intraocular Delivery

View page
US Patent:
20140275091, Sep 18, 2014
Filed:
Mar 15, 2013
Appl. No.:
13/815870
Inventors:
- Menlo Park CA, US
Tilmann M. Brotz - Menlo Park CA, US
International Classification:
A61K 9/00
US Classification:
5142378, 514480, 514367, 514352, 514315
Abstract:
Provided herein is a pharmaceutical formulation comprising a GGA derivative in the form of an eye drop. Also provided herein are methods of treating neural diseases or disorders by administering such pharmaceutical formulations.

Therapeutic Uses Of Geranylgeranyl Acetone And Derivatives Thereof

View page
US Patent:
20140275280, Sep 18, 2014
Filed:
Mar 15, 2013
Appl. No.:
13/815740
Inventors:
- MENLO PARK CA, US
Tilmann M. Brotz - Menlo Park CA, US
International Classification:
A61K 31/121
US Classification:
514675
Abstract:
Provide herein are methods of treating inflammatory bowel disease with geranylgeranyl acetone (GGA) and/or derivatives thereof. Also provided are methods of treating chronic liver disease (CLD) with geranylgeranyl acetone (GGA) and/or derivatives thereof. Still further are provided methods for treating other hepatic and cardiac disorders.

Geranylgeranyl Acetone And Derivatives Thereof For Intranasal Administration

View page
US Patent:
20140275281, Sep 18, 2014
Filed:
Mar 15, 2013
Appl. No.:
13/815741
Inventors:
- MENLO PARK CA, US
Tilmann M. Brotz - Menlo Park CA, US
Assignee:
COYOTE PHARMACEUTICALS, INC. - MENLO PARK CA
International Classification:
A61K 31/121
US Classification:
514675
Abstract:
Provide herein are intranasal compositions which include geranylgeranyl acetone (GGA) and/or derivatives thereof and methods for treating a neural disease, disorder or condition with the same.
Control profile
Tilmann M Brotz from Berkeley, CA, age ~60 Get Report